Comparative Pharmacology
Head-to-head clinical analysis: KETEK versus NITROFURANTOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETEK versus NITROFURANTOIN.
KETEK vs NITROFURANTOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or inhibit bacterial ribosomal proteins, DNA, RNA, and metabolic enzymes, leading to bacterial cell death.
Telithromycin 800 mg orally once daily for 7-10 days.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 50-100 mg orally four times daily for 7 days (symptomatic uncomplicated UTI). Extended-release: 100 mg orally twice daily for 7 days.
None Documented
None Documented
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Clinical Note
moderateNitrofurantoin + Norfloxacin
"The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Rolapitant
Normal renal function: 20-60 minutes; impaired function: prolonged up to 1-2 hours, clinically significant due to urinary concentration requirement
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Renal: ~40% unchanged via glomerular filtration and tubular secretion, biliary/fecal: <1%
Category C
Category D/X
Antibiotic, Ketolide
Antibiotic
"The serum concentration of Rolapitant can be increased when it is combined with Nitrofurantoin."